Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Returns Japan Rights for Some Amgen Products
June 27, 2016
- Teijin Pharma Will Block Feburic Generic Erosions by Expanding Indications: President
June 24, 2016
- Cellular Dynamics, US National Eye Institute Ink Pact to Advance Cell Transplantation Therapy for AMD
June 24, 2016
- Univ. of Tokyo, Astellas to Codevelop Rice-Based Oral Cholera Vaccine
June 24, 2016
- Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
June 23, 2016
- Asahi Kasei Inks Collaboration with Finland’s Orion on Pain Therapies
June 23, 2016
- Interview: Bayer Yakuhin Chief Spearheading Initiatives to Trigger Behavior Change in Employees
June 23, 2016
- Fujifilm Inks 1st License Deal for Avigan Patents with Chinese Pharma
June 23, 2016
- Takeda to Partner with US NPO for Joint Program to Explore Lead Compounds for TB Therapies
June 23, 2016
- Bayer Japan Revs Up Drive to Spark Behavior Change, Offers Patient Insights to Back Office Staffers
June 22, 2016
- Takao Hayakawa Tapped as New Chief of Kaketsuken
June 22, 2016
- Takeda Kicks Off PIIb Trial for Norovirus Vaccine in US
June 22, 2016
- AnGes MG Alters Global Collategene Strategy, Initial Focus Now on US
June 21, 2016
- Mitsubishi Tanabe Files US NDA for ALS Drug Edaravone, Eyes Nod by March-End
June 21, 2016
- Jannie Oosthuizen to Lead MSD Japan from July
June 21, 2016
- Cyramza Earns Lung Cancer Indication in Japan
June 21, 2016
- Co-Dio AG Makes Debut; Kipres, Ecard AGs to Hit Market Early September
June 20, 2016
- AMED-Backed Neuropathic Pain Drug Now in PI: Nippon Chemiphar, Kyushu University
June 20, 2016
- Takeda Gains Access to US Cancer Genomic Network
June 20, 2016
- Takeda’s Partnership with Tri-I TDI Now Encompasses Antibody Drug Discovery
June 20, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…